Here are the top health headlines for the week of Jan. 19, 2025. A nasal spray derived from ketamine gets federal clearance ...
A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.
The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.